|
PEX2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.1005419625908E-13 |
| Normal-vs-Stage2 |
2.24469998144627E-09 |
| Normal-vs-Stage3 |
2.70894418008538E-14 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
7.004600E-01 |
| Stage1-vs-Stage3 |
6.657600E-02 |
| Stage1-vs-Stage4 |
2.353200E-04 |
| Stage2-vs-Stage3 |
3.716000E-01 |
| Stage2-vs-Stage4 |
2.671500E-02 |
| Stage3-vs-Stage4 |
1.016840E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.73030999999213E-05 |
| Normal-vs-Asian |
1.69499969615572E-10 |
| Caucasian-vs-AfricanAmerican |
3.872800E-01 |
| Caucasian-vs-Asian |
6.039400E-01 |
| AfricanAmerican-vs-Asian |
6.963600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.05391259555654E-14 |
| Normal-vs-Female |
1.62536650805123E-12 |
| Male-vs-Female |
3.725400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.35145236615608E-12 |
| Normal-vs-Age(41-60Yrs) |
9.02611319020252E-14 |
| Normal-vs-Age(61-80Yrs) |
1.63113966777928E-12 |
| Normal-vs-Age(81-100Yrs) |
1.677270E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.534600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.309800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.288200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.177200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.230400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.794200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.41679999999756E-05 |
| Classical-VS-Follicular |
4.214800E-01 |
| Classical-VS-Other |
9.511400E-01 |
| Classical-VS-Normal |
1.6251444634463E-12 |
| Tall-VS-Follicular |
1.754450E-04 |
| Tall-VS-Other |
2.748800E-01 |
| Tall-VS-Normal |
1.62492241884138E-12 |
| Follicular-VS-Other |
7.683000E-01 |
| Follicular-VS-Normal |
6.86169999708497E-08 |
| Other-VS-Normal |
2.637600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.91633384108536E-12 |
| Normal-vs-N1 |
2.44249065417534E-15 |
| N0-vs-N1 |
6.977400E-03 |
|
|
